| Followers | 52 |
| Posts | 14331 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2014 |
Monday, February 16, 2026 3:09:14 PM
Yep, over $11. Will be setting my alarm early for Tuesday morning although my prostate has me up by that time anyway. Gonna sell half on positive news, and all of it if it skyrockets. I know a long time ago, Sleven said he would sell on news and not hold but the last time I had a message from him IIRC he said he didn’t have a position here. I might be wrong. Good luck to us all.
Recent OCUL News
- Ocular Therapeutix™ to Host Investor Day on June 17, 2026 • GlobeNewswire Inc. • 04/22/2026 11:00:00 AM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/14/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/13/2026 09:15:06 PM
- Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD • GlobeNewswire Inc. • 04/13/2026 11:00:00 AM
- Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April • GlobeNewswire Inc. • 04/01/2026 11:00:00 AM
- Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/09/2026 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2026 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 11:19:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 11:18:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/25/2026 11:17:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2026 11:13:43 PM
- Ocular Therapeutix™ to Participate in March Investor Conferences • GlobeNewswire Inc. • 02/24/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 09:23:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 09:21:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 09:18:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/23/2026 09:16:55 PM
- Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations • GlobeNewswire Inc. • 02/23/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2026 09:36:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:31:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:29:16 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/18/2026 01:28:28 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 11:13:23 PM
- Ocular Therapeutix plunges 35% despite positive wet AMD Phase 3 data • IH Market News • 02/17/2026 03:35:10 PM
- Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD • GlobeNewswire Inc. • 02/17/2026 12:00:00 PM
- Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026 • GlobeNewswire Inc. • 02/13/2026 10:00:00 PM
